Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Cardiol Therapeutics Inc Class A (CRDL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: CRDL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.74
1 Year Target Price $7.74
| 1 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.34% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 86.43M USD | Price to earnings Ratio - | 1Y Target Price 7.74 |
Price to earnings Ratio - | 1Y Target Price 7.74 | ||
Volume (30-day avg) 5 | Beta 0.62 | 52 Weeks Range 0.77 - 2.24 | Updated Date 10/18/2025 |
52 Weeks Range 0.77 - 2.24 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.34 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -108.74% | Return on Equity (TTM) -276.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 74138750 | Price to Sales(TTM) 1069.35 |
Enterprise Value 74138750 | Price to Sales(TTM) 1069.35 | ||
Enterprise Value to Revenue 178.81 | Enterprise Value to EBITDA 0.3 | Shares Outstanding 83729448 | Shares Floating 80582895 |
Shares Outstanding 83729448 | Shares Floating 80582895 | ||
Percent Insiders 4.11 | Percent Institutions 8.33 |
Upturn AI SWOT
Cardiol Therapeutics Inc Class A
Company Overview
History and Background
Cardiol Therapeutics Inc. is a biotechnology company focused on the research and clinical development of pharmaceutical cannabidiol (CBD) and other anti-inflammatory therapies for the treatment of cardiovascular disease. Founded in 2016, the company has primarily focused on developing therapies to reduce inflammation and fibrosis in cardiovascular conditions.
Core Business Areas
- Cardiovascular Disease Therapeutics: Developing pharmaceutical CBD formulations for treating acute myocarditis and recurrent pericarditis, focusing on reducing inflammation and fibrosis in the heart.
Leadership and Structure
David Elsley is the President and CEO. The company has a board of directors overseeing strategic direction and management.
Top Products and Market Share
Key Offerings
- CardiOlRxu2122: A pharmaceutical cannabidiol formulation for the treatment of acute myocarditis and recurrent pericarditis. The market is relatively niche, targeting patients with these specific cardiovascular conditions. Competitors include standard-of-care treatments like NSAIDs, colchicine, and corticosteroids, as well as other companies developing novel anti-inflammatory therapies.
Market Dynamics
Industry Overview
The cardiovascular disease therapeutics market is large and competitive, with significant unmet needs in specific inflammatory conditions like myocarditis and pericarditis. There is growing interest in anti-inflammatory therapies and the potential of CBD in treating these conditions.
Positioning
Cardiol Therapeutics is positioning itself as a leader in the development of pharmaceutical CBD for cardiovascular diseases, focusing on specific indications with high unmet needs. Their competitive advantage lies in their proprietary formulations and focus on clinical validation.
Total Addressable Market (TAM)
The total addressable market for acute myocarditis and recurrent pericarditis is estimated to be in the hundreds of millions of dollars. Cardiol Therapeutics is positioned to capture a significant portion of this market with its targeted therapy.
Upturn SWOT Analysis
Strengths
- Proprietary pharmaceutical CBD formulations
- Focus on specific cardiovascular indications with unmet needs
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited commercialized products
- Reliance on clinical trial success
- Small market capitalization
- Dependence on capital markets for funding
Opportunities
- Positive clinical trial results
- Regulatory approval for CardiOlRxu2122
- Expansion into other cardiovascular indications
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established cardiovascular therapies
- Changes in CBD regulations
- Generic competition if IP not well protected
Competitors and Market Share
Key Competitors
- HLGNF
- JAZZ
- GWPH
- AKBA
Competitive Landscape
Cardiol Therapeutics faces competition from established cardiovascular therapies and other companies developing novel anti-inflammatory treatments. Its competitive advantage lies in its proprietary CBD formulations and focus on specific indications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily in terms of research and development activities and pipeline advancement.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approval of CardiOlRxu2122.
Recent Initiatives: Recent initiatives include advancing clinical trials for CardiOlRxu2122 in myocarditis and pericarditis, and exploring potential partnerships.
Summary
Cardiol Therapeutics is a development-stage company with a promising pharmaceutical CBD product, CardiOlRxu2122, targeting inflammatory cardiovascular diseases. Its success is highly dependent on positive clinical trial results and regulatory approval. While the company has a focused approach and a strong IP portfolio, it faces significant risks due to its limited commercialized products and reliance on external funding. Investors should closely monitor clinical trial outcomes and regulatory developments for the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cardiol Therapeutics Inc Class A
Exchange NASDAQ | Headquaters Oakville, ON, Canada | ||
IPO Launch date 2019-01-15 | President, CEO & Director Mr. David G. Elsley MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 18 | Website https://www.cardiolrx.com |
Full time employees 18 | Website https://www.cardiolrx.com | ||
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.